Sai Life Sciences (NSE:SAILIFE) Other Stockholders Equity: ₹24,625 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
18 GF Score
Price ₹1,272.00
! 5 Warning Signs
View Full Analysis

What is Sai Life Sciences Other Stockholders Equity?

Sai Life Sciences NSE:SAILIFE -1.77% 18 Other Stockholders Equity is ₹24,625 Mil as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Sai Life Sciences's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹24,625 Mil.

Sai Life Sciences's quarterly Other Stockholders Equity declined from Sep. 2025 (₹22,487 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹24,625 Mil).

Sai Life Sciences's annual Other Stockholders Equity declined from Mar. 2024 (₹145 Mil) to Mar. 2025 (₹98 Mil) but then increased from Mar. 2025 (₹98 Mil) to Mar. 2026 (₹24,625 Mil).

Sai Life Sciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Other Stockholders Equity Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
109.81 129.41 145.18 98.46 24,625.10

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.46 0.00 22,487.24 0.00 24,625.10
NSE:SAILIFE
18GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹24,625 Mil mean?
Sai Life Sciences (NSE:SAILIFE) has a Other Stockholders Equity of ₹24,625 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sai Life Sciences and its competitors.
Is Sai Life Sciences' Other Stockholders Equity too high?
Sai Life Sciences' current Other Stockholders Equity is ₹24,625 Mil. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Other Stockholders Equity compare to TMO and DHR?
Sai Life Sciences' Other Stockholders Equity of ₹24,625 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current Other Stockholders Equity is ₹24,625 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Other Stockholders Equity of ₹24,625 Mil. The current Other Stockholders Equity is ₹24,625 Mil. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Other Stockholders Equity is ₹24,625 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score

Get the complete analysis for NSE:SAILIFE

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,272.00
Price